Rajiv Rathod, MD
Ophthalmology · Santa Ana, CANPI 1821201351
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 43.5% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $255.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$37K
- Genentech, Inc.$14K
- Alimera Sciences, Inc.$12K
- AbbVie$8K
- Genentech USA, Inc.$6K
- Eyepoint US, Inc.$2K
- plus $6K from 25 others
Across 43 payments — averaging $6288.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$239K
- Alimera Sciences, Inc.$21K
- ANI Pharmaceuticals, Inc.$10K
What the payments were for
- Consulting fees$20,98925%
- Speaking & faculty fees$47,68256%
- Travel & lodging$4,3095%
- Food & beverage$12,36514%
- Education$80%
- Entertainment$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 76 | $37,174 |
| Genentech, Inc. | 13 | $13,915 |
| Alimera Sciences, Inc. | 31 | $12,280 |
| AbbVie(2 entities) | 58 | $8,232 |
| Genentech USA, Inc. | 38 | $6,423 |
| Eyepoint US, Inc. | 6 | $1,843 |
| Alcon | 12 | $1,080 |
| Apellis Pharmaceuticals, Inc. | 11 | $1,023 |
| Astellas Pharma US Inc | 14 | $606 |
| Mallinckrodt Hospital Products Inc. | 31 | $599 |
| Novartis | 6 | $524 |
| ANI Pharmaceuticals, Inc. | 5 | $326 |
| Samsara Vision | 2 | $261 |
| Aerie Pharmaceuticals, Inc. | 3 | $155 |
| Spark Therapeutics, Inc. | 2 | $144 |
| Optos, Inc. | 1 | $142 |
| Thrombogenics, Inc. | 1 | $117 |
| Regeneron | 1 | $116 |
| Harrow Eye, LLC | 4 | $99 |
| Ocular Therapeutix, Inc. | 2 | $98 |
| Oyster Point Pharma, Inc. | 3 | $69 |
| Amgen(2 entities) | 3 | $54 |
| Coherus Oncology, Inc. | 2 | $44 |
| Biogen | 2 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $22 |
| Sandoz | 1 | $20 |
| Glaukos Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$35,526
- Iluvien$11,602
- Lucentis$8,430
- VABYSMO$5,713
- OZURDEX$4,751
- YUTIQ$1,904
- Syfovre$578
- Constellation$520
- NGENUITY$431
- EYLEA$358
- Implantable Miniature Telescope$261
- Izervay$250
- BEOVU$238
- PURIFIED CORTROPHIN GEL$197
- Non-Covered Product$150
- P200DTx$142
- P200T$142
- P200TE$142
- P200TxE$142
- LUMIGAN$124
How this compares
$85,494 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 44 | $21,189 |
| RestasisCyclosporine | 15 | $16,566 |
| TyrvayaVarenicline Tartrate | 17 | $11,129 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $10,225 |
| Prednisolone Acetate | 236 | $8,966 |
| XiidraLifitegrast | 11 | $8,878 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 59 | $8,444 |
| ProlensaBromfenac Sodium | 21 | $8,019 |
| Cyclosporine | 21 | $7,357 |
| RhopressaNetarsudil Mesylate | 16 | $6,810 |
| Difluprednate | 56 | $5,603 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,927 |
| Brimonidine Tartrate | 49 | $3,630 |
| Atropine Sulfate | 95 | $2,976 |
| Loteprednol Etabonate | 19 | $2,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $8,232 | $47,98090 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $69 | $11,12917 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $25 | $10,68540 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $155 | $6,81016 claims |
| AlconSimbrinza | $1,080 | $4,92720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Santa Ana
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.